Response Biomedical, a developer and marketer of rapid on-site diagnostic tests, has introduced its Ramp technology in the 3M Rapid Detection Flu A+B test, officially launching the Ramp influenza A/B Assay in the US.
The test is branded by 3M as the 3M Rapid Detection Flu A+B Test. This rapid flu test provides hospital and physician office laboratories reliable and objective electronic results in approximately 15 minutes and in a clinical study has been shown to be more sensitive for influenza A and B than the hospital competitor, the BinaxNOW influenza A & B Test.
The Ramp system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories.
Ramp clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza. In the non-clinical market, Ramp Tests are currently provided for the environmental detection of West Nile Virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin, the company said.
Wayne Kay, CEO of Response Biomedical, said: “The 3M Rapid Detection Flu A+B test, powered by the RAMP technology, is the first major clinical test to be launched by a partner in the US. It is further evidence of the broad platform of the RAMP technology that we have developed to meet the market needs of our partners, such as 3M, Roche Diagnostics and Shionogi.
“Besides the launch of the 3M product, we are excited about the introduction of our comprehensive cardiac line by Roche Diagnostics, expected in the first quarter of 2009.”
Comments